GSK appoints new sales and marketing heads in China; Mylan bids $9B+ for Sweden's Meda;

@FiercePharma: Top-read on FiercePharmaManufacturing Thurs: Hospira recalls 7 lots of propofol and one of lidocaine Story | Follow @FiercePharma

@TracyStaton: @Indianmarketeer: Novartis seems to think it can pump up sales of GSK's drugs better than GSK could. But as you say, time will tell. | Follow @TracyStaton

@EricPFierce: A large block of #AstraZeneca shareholders voted against the company's pay plan and one of its directors. More | Follow @EricPFierce

@CarlyHFierce: Arena - Television Ads Raise Awareness. Report from SeekingAlpha | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) has appointed two executives to new roles overseeing sales and marketing in China after authorities accused the firm of corruption last year, a person with direct knowledge of the decision told Reuters. Report

> Mylan ($MYL) has made a new bid for Sweden's Meda, this time at more than $9 billion. More

> The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on GSK melanoma drug Mekinist. Release

> Prestige Brands has reached an agreement to buy Insight Pharmaceuticals for $750 million. Story (sub. req.)

> The FDA has approved a new plant for Strides Arcolab in Bangalore, where it will manufacture oral medicines. Story

> Celgene ($CELG) is paying Ireland's Nogra Pharma $710 million upfront to buy its late-stage product for Crohn's disease and other gastrointestinal disorders. Story

Medical Device News

@FierceMedDev: Stryker's sales jump after string of M&A deals. More | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Zimmer buying fellow orthopedics company Biomet for $13.35 billion. | Follow @VarunSaxena2

@EmilyWFierce: Security holes in a number of commonly used medical devices could leave them open to attack. Article | Follow @EmilyWFierce

@MichaelGFierce: ICYMI: DNA nanocages that act like viruses bypass the immune system to deliver drugs. Story | Follow @MichaelGFierce

> Roche's HPV test gets FDA approval for primary cervical cancer screen. More

> Ariosa tests the waters with plans for a $60M IPO. News

> Covidien quarterly sales up 3% to $2.6 billion. Article

Biotech News

@FierceBiotech: EuroBiotech Report: GlaxoSmithKline & Novartis reshape EU biotech, Celgene, Hyperion in Euro deals, U.K. cell therapy grows, and more. Report | Follow @FierceBiotech

@JohnCFierce: Pyott told me back in January he could easily spend $10 billion on buyouts. Though that's not Shire territory. Story from January | Follow @JohnCFierce

@DamianFierce: ICYMI: Celgene opens down 5%. Perhaps a $710M deal didn't thrill investors who just watched R&D costs drag profits. | Follow @DamianFierce

@EmilyMFierce: Blood of world's oldest woman hints at limits of life. More | Follow @EmilyMFierce

> Arch Venture swings for a $250M fund to bet on biotechs. Story

> Buyout buzz: Allergan made a pass at Shire before Valeant came calling. Article

> Radius dials up a $92M IPO pitch despite tepid market for biotechs. News

And Finally... The FDA has proposed its rules for e-cigarette regulation. More

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.